NCT00569842已完成不适用
Investigation of the Cylex® ImmuKnow® Assay
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
研究概览
简要总结
Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:
- •Acute leukemia
- •Non-Hodgkin's Lymphoma
- •Chronic lymphocytic leukemia
- •Hodgkin's disease
- •Multiple myeloma
- •Myelodysplastic Syndromes
- •Myeloproliferative Disorders
- •Aplastic Anemia
- •Chronic myelogenous leukemia
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell TransplantationGraft Versus Host DiseaseHematologic MalignanciesNCT00146614Dana-Farber Cancer Institute105
已完成
不适用
Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host DiseaseGraft vs Host DiseaseNCT00632658Ann & Robert H Lurie Children's Hospital of Chicago24
已完成
1 期
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHDGraft Versus Host DiseaseAllogeneic Hematopoietic Cell Transplant RecipientNCT01911039Laura Johnston14
Unknown
不适用
Toward Immune Biomarkers for Tolerance and GvHD in HumansBone Marrow TransplantationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationNCT02319226Assistance Publique - Hôpitaux de Paris60
已完成
2 期
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckNCT01218048Robert Ferris40